# Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC

Source: [nature.com](https://www.nature.com/articles/s41571-026-01233-z) · 2026-11-09 · Medicine
Page: https://themorning.science/story/divarasib-outperforms-first-generation-kras-g12c-inhibitors-in-nsclc-098f8272ad7728a1
Kind: research · Impact: medium

## In brief

- Published online in Nature Reviews Clinical Oncology on 9 November 2026, with DOI 10.1038/s41571-026-01233-z.
- The article's headline reports that divarasib outperforms first-generation KRAS-G12C inhibitors in non-small cell lung cancer (NSCLC).
- The source material provided here gives only the headline and citation, so trial design, sample size and effect sizes are not available.

## Why it matters

It reports a comparison between a newer KRAS-G12C inhibitor and earlier agents in NSCLC, which bears on treatment choices and future trial design in this patient population.

## Timeline

- 2026-11-09: Article published online in Nature Reviews Clinical Oncology

## Coverage

- [Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC](https://www.nature.com/articles/s41571-026-01233-z) — nature.com, 2026-11-09

Tags: kras, nsclc, oncology, divarasib, lung-cancer

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science